HC Wainwright Has Positive Forecast for TEVA FY2026 Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, November 4th. HC Wainwright analyst D. Tsao now expects that the company will earn $1.96 per share for the year, up from their previous estimate of $1.94. HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $1.97 per share. HC Wainwright also issued estimates for Teva Pharmaceutical Industries’ Q4 2026 earnings at $0.64 EPS, Q1 2027 earnings at $0.63 EPS, Q2 2027 earnings at $0.74 EPS, Q3 2027 earnings at $0.79 EPS, Q4 2027 earnings at $0.91 EPS and FY2027 earnings at $3.07 EPS.

Several other research firms also recently weighed in on TEVA. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Leerink Partners raised their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Finally, Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $47.23.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $42.38 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. The stock’s fifty day moving average is $39.75 and its two-hundred day moving average is $34.90. Teva Pharmaceutical Industries has a 52 week low of $24.01 and a 52 week high of $43.34. The company has a market capitalization of $49.38 billion, a PE ratio of 98.55, a price-to-earnings-growth ratio of 4.04 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the previous year, the business earned $0.78 EPS. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders have sold 420,942 shares of company stock worth $16,572,473 in the last ninety days. 0.54% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the business. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $1,648,000. USS Investment Management Ltd bought a new position in Teva Pharmaceutical Industries in the third quarter worth approximately $10,840,000. WealthTrust Axiom LLC bought a new position in Teva Pharmaceutical Industries in the third quarter worth approximately $279,000. Ieq Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 7.8% during the third quarter. Ieq Capital LLC now owns 44,377 shares of the company’s stock worth $1,757,000 after buying an additional 3,207 shares during the period. Finally, Focus Advisor Solutions LLC lifted its holdings in Teva Pharmaceutical Industries by 45.2% during the third quarter. Focus Advisor Solutions LLC now owns 13,920 shares of the company’s stock worth $551,000 after buying an additional 4,333 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.